Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ADTX 
Aditxt Inc. (ADTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ADTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $61
1 Year Target Price $61
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.23M USD | Price to earnings Ratio - | 1Y Target Price 61 |
Price to earnings Ratio - | 1Y Target Price 61 | ||
Volume (30-day avg) 1 | Beta 1.33 | 52 Weeks Range 1.28 - 27200.00 | Updated Date 06/30/2025 |
52 Weeks Range 1.28 - 27200.00 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -25.94 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -550895.36% |
Management Effectiveness
Return on Assets (TTM) -46.32% | Return on Equity (TTM) -204.37% |
Valuation
Trailing PE - | Forward PE 0.37 | Enterprise Value 6829798 | Price to Sales(TTM) 58.45 |
Enterprise Value 6829798 | Price to Sales(TTM) 58.45 | ||
Enterprise Value to Revenue 123.45 | Enterprise Value to EBITDA 0.02 | Shares Outstanding 2431150 | Shares Floating 2120031 |
Shares Outstanding 2431150 | Shares Floating 2120031 | ||
Percent Insiders - | Percent Institutions 2.71 |
Analyst Ratings
Rating 1 | Target Price 61 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Aditxt Inc.
Company Overview
History and Background
Aditxt, Inc., founded in 2017, is a biotech company focused on technologies impacting the immune system. It aims to develop and commercialize technologies for monitoring, modifying, and restoring immune function. Their approach has evolved through acquisitions and internal development.
Core Business Areas
- AditxtScore: A diagnostic platform designed to assess an individual's immune system status using a simple blood test. It aims to provide personalized insights for managing immune health.
- AditxtReprogramming: Focuses on technologies aimed at reprogramming the immune system to address conditions like allergies and autoimmune diseases. This segment is in the early stages of development.
- AditxtRx: Aims to develop novel therapeutics targeting immune-related disorders. Details on specific drug candidates and their progress are limited, but it represents a future growth area.
Leadership and Structure
Aditxt is led by a management team with experience in biotech and healthcare. The organizational structure is relatively small, reflecting its status as a development-stage company.
Top Products and Market Share
Key Offerings
- AditxtScore: AditxtScore is Aditxt's primary commercial product. It is a blood test that provides a snapshot of a person's current immune status. Market share data is currently not publicly available, but competition includes general blood tests and other specialized immune function assays offered by companies like LabCorp (LH) and Quest Diagnostics (DGX).
Market Dynamics
Industry Overview
The immune monitoring and modification market is growing, driven by increased awareness of immune health and advancements in diagnostics and therapeutics. Personalized medicine and preventative healthcare are key trends.
Positioning
Aditxt aims to be a leader in personalized immune health management through its AditxtScore and future reprogramming technologies. Its competitive advantage lies in its integrated approach.
Total Addressable Market (TAM)
The TAM for immune monitoring and modification is estimated to be in the billions of dollars. Aditxt is positioned to capture a share of this market with its AditxtScore platform and future therapeutic developments. A specific estimate for TAM is difficult to ascertain due to diverse market segments.
Upturn SWOT Analysis
Strengths
- Proprietary AditxtScore technology
- Integrated approach to immune monitoring and modification
- Potential for personalized medicine applications
Weaknesses
- Limited revenue generation
- Dependence on funding for R&D
- Early stage of development for many products
- Relatively small team compared to competitors
- Past compliance issues
Opportunities
- Partnerships with healthcare providers
- Expansion of AditxtScore applications
- Development of novel immune therapies
- Growing demand for personalized healthcare
Threats
- Competition from established diagnostic companies
- Regulatory hurdles for new technologies
- Market acceptance of AditxtScore
- Economic downturn impacting healthcare spending
- Dilution from frequent stock issuances
Competitors and Market Share
Key Competitors
- LH
- DGX
- ILMN
Competitive Landscape
Aditxt competes with larger, more established diagnostic companies. Its advantage lies in its focused approach to immune health, but its disadvantage is its limited resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited, primarily focused on developing the AditxtScore platform.
Future Projections: Future growth is dependent on the successful commercialization of AditxtScore and the development of new technologies. Analyst estimates are speculative due to the company's early stage.
Recent Initiatives: Recent initiatives include expanding the AditxtScore's applications and exploring partnerships for commercialization. There have also been some controversies around management actions.
Summary
Aditxt is a development-stage biotech company with a focus on immune health. AditxtScore shows promise, but the company faces significant challenges, including limited revenue, high operating expenses, and competition from larger players. Future success depends on successful commercialization and further technological advancements. The company needs to be wary of dilution from stock issuances and market acceptance of AditxtScore.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q), Aditxt Inc. 's investor relations website
Disclaimers:
This analysis is based on publicly available information and does not constitute investment advice. Market share data is estimated and may not be precise. The company's future performance is subject to significant risks and uncertainties.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aditxt Inc.
Exchange NASDAQ | Headquaters Mountain View, CA, United States | ||
IPO Launch date 2020-06-30 | Co-Founder, Chairman, CEO & President Mr. Amro A. Albanna | ||
Sector Healthcare | Industry Biotechnology | Full time employees 26 | Website https://www.aditxt.com |
Full time employees 26 | Website https://www.aditxt.com | ||
Aditxt, Inc., a commercial-stage company, discovers and develops products in the areas of immune health, precision health, population health, women's health, and neurologic health. The company develops AditxtScore that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.